| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medical Oncology | 68 | 2024 | 360 | 13.670 |
Why?
|
| Neoplasms | 167 | 2024 | 2898 | 13.500 |
Why?
|
| Antineoplastic Agents | 96 | 2024 | 2360 | 10.980 |
Why?
|
| Clinical Trials as Topic | 66 | 2021 | 1169 | 8.030 |
Why?
|
| Precision Medicine | 29 | 2024 | 395 | 6.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 78 | 2023 | 2438 | 4.410 |
Why?
|
| Colorectal Neoplasms | 36 | 2023 | 938 | 4.380 |
Why?
|
| Molecular Targeted Therapy | 18 | 2021 | 266 | 4.370 |
Why?
|
| Fluorouracil | 46 | 2017 | 556 | 2.800 |
Why?
|
| Humans | 350 | 2024 | 86656 | 2.650 |
Why?
|
| Drug Approval | 13 | 2018 | 62 | 2.460 |
Why?
|
| Biomarkers, Tumor | 24 | 2019 | 1464 | 2.350 |
Why?
|
| United States | 71 | 2022 | 6674 | 2.340 |
Why?
|
| Biomedical Research | 17 | 2021 | 376 | 2.280 |
Why?
|
| Societies, Medical | 19 | 2021 | 573 | 2.230 |
Why?
|
| Biosimilar Pharmaceuticals | 4 | 2022 | 20 | 2.100 |
Why?
|
| Melanoma | 3 | 2023 | 459 | 2.010 |
Why?
|
| Delivery of Health Care | 9 | 2024 | 426 | 1.950 |
Why?
|
| Mutation | 15 | 2024 | 3977 | 1.930 |
Why?
|
| Antimetabolites, Antineoplastic | 17 | 2011 | 236 | 1.840 |
Why?
|
| Breast Neoplasms | 33 | 2024 | 2904 | 1.750 |
Why?
|
| Research Design | 22 | 2023 | 594 | 1.640 |
Why?
|
| Leucovorin | 29 | 2017 | 218 | 1.640 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 14 | 2023 | 1075 | 1.540 |
Why?
|
| Colonic Neoplasms | 10 | 2018 | 557 | 1.460 |
Why?
|
| Lung Neoplasms | 25 | 2023 | 2262 | 1.400 |
Why?
|
| Deoxycytidine | 13 | 2011 | 237 | 1.370 |
Why?
|
| Genomics | 8 | 2024 | 720 | 1.310 |
Why?
|
| Patient Selection | 12 | 2018 | 686 | 1.300 |
Why?
|
| Immunotherapy | 11 | 2019 | 631 | 1.260 |
Why?
|
| Patient Participation | 4 | 2016 | 216 | 1.240 |
Why?
|
| United States Food and Drug Administration | 15 | 2019 | 127 | 1.230 |
Why?
|
| Disclosure | 4 | 2019 | 108 | 1.200 |
Why?
|
| Uracil | 11 | 2002 | 72 | 1.120 |
Why?
|
| Randomized Controlled Trials as Topic | 19 | 2020 | 864 | 1.120 |
Why?
|
| Genes, ras | 3 | 2017 | 96 | 1.090 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 429 | 1.080 |
Why?
|
| Drug Design | 8 | 2010 | 124 | 0.990 |
Why?
|
| Cetuximab | 4 | 2020 | 113 | 0.960 |
Why?
|
| Genetic Testing | 4 | 2020 | 535 | 0.960 |
Why?
|
| Early Detection of Cancer | 7 | 2020 | 395 | 0.950 |
Why?
|
| Phenylurea Compounds | 1 | 2024 | 114 | 0.930 |
Why?
|
| Aged | 115 | 2021 | 18407 | 0.920 |
Why?
|
| Data Accuracy | 1 | 2023 | 31 | 0.910 |
Why?
|
| Gastrointestinal Neoplasms | 6 | 2014 | 106 | 0.890 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2024 | 138 | 0.850 |
Why?
|
| Information Dissemination | 5 | 2023 | 103 | 0.840 |
Why?
|
| Middle Aged | 118 | 2021 | 25027 | 0.820 |
Why?
|
| Female | 142 | 2024 | 44566 | 0.820 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 185 | 0.810 |
Why?
|
| Trastuzumab | 6 | 2023 | 68 | 0.810 |
Why?
|
| ErbB Receptors | 3 | 2015 | 486 | 0.800 |
Why?
|
| Antibodies, Monoclonal | 13 | 2022 | 1380 | 0.800 |
Why?
|
| National Cancer Institute (U.S.) | 4 | 2020 | 70 | 0.790 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 111 | 0.790 |
Why?
|
| Cisplatin | 25 | 2005 | 612 | 0.780 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2020 | 127 | 0.780 |
Why?
|
| Antibodies, Monoclonal, Humanized | 10 | 2023 | 931 | 0.770 |
Why?
|
| Pandemics | 4 | 2022 | 737 | 0.760 |
Why?
|
| Oncologists | 2 | 2020 | 36 | 0.760 |
Why?
|
| Registries | 6 | 2022 | 703 | 0.750 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 193 | 0.740 |
Why?
|
| Oxidoreductases | 6 | 2002 | 112 | 0.730 |
Why?
|
| Financial Support | 1 | 2019 | 7 | 0.730 |
Why?
|
| Clinical Decision-Making | 5 | 2021 | 257 | 0.720 |
Why?
|
| Neoplasm Staging | 15 | 2018 | 1938 | 0.700 |
Why?
|
| Rural Population | 1 | 2020 | 136 | 0.700 |
Why?
|
| Drug Delivery Systems | 4 | 2011 | 178 | 0.700 |
Why?
|
| Drug Industry | 4 | 2024 | 54 | 0.700 |
Why?
|
| Insurance Benefits | 1 | 2019 | 8 | 0.690 |
Why?
|
| Periodicals as Topic | 2 | 2019 | 168 | 0.690 |
Why?
|
| Treatment Outcome | 36 | 2021 | 7982 | 0.680 |
Why?
|
| Male | 125 | 2023 | 40995 | 0.680 |
Why?
|
| Practice Guidelines as Topic | 8 | 2020 | 1037 | 0.670 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2019 | 103 | 0.670 |
Why?
|
| Cooperative Behavior | 6 | 2015 | 176 | 0.670 |
Why?
|
| Drug Discovery | 3 | 2019 | 103 | 0.660 |
Why?
|
| Genome, Human | 5 | 2017 | 756 | 0.660 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.660 |
Why?
|
| Receptor, ErbB-2 | 5 | 2023 | 224 | 0.650 |
Why?
|
| Adult | 102 | 2021 | 25648 | 0.650 |
Why?
|
| Electronic Health Records | 3 | 2019 | 320 | 0.640 |
Why?
|
| Famous Persons | 1 | 2018 | 14 | 0.640 |
Why?
|
| Enzyme Inhibitors | 6 | 2002 | 639 | 0.640 |
Why?
|
| Skin Ulcer | 1 | 2018 | 25 | 0.640 |
Why?
|
| Hematology | 1 | 2018 | 29 | 0.640 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 315 | 0.640 |
Why?
|
| Health Care Costs | 5 | 2017 | 238 | 0.640 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 300 | 0.640 |
Why?
|
| Clinical Trials, Phase III as Topic | 10 | 2018 | 172 | 0.630 |
Why?
|
| Off-Label Use | 2 | 2015 | 16 | 0.630 |
Why?
|
| Community Health Services | 1 | 2019 | 80 | 0.630 |
Why?
|
| Decision Support Techniques | 2 | 2016 | 160 | 0.610 |
Why?
|
| Value-Based Purchasing | 1 | 2017 | 4 | 0.610 |
Why?
|
| Pharmacogenetics | 5 | 2010 | 434 | 0.590 |
Why?
|
| Camptothecin | 10 | 2017 | 189 | 0.570 |
Why?
|
| Leukemia | 6 | 2013 | 320 | 0.570 |
Why?
|
| Organizations | 2 | 2013 | 17 | 0.560 |
Why?
|
| Multicenter Studies as Topic | 6 | 2016 | 159 | 0.560 |
Why?
|
| Methotrexate | 14 | 1996 | 249 | 0.550 |
Why?
|
| Chemotherapy, Adjuvant | 15 | 2018 | 468 | 0.550 |
Why?
|
| Liver Neoplasms | 6 | 2018 | 736 | 0.540 |
Why?
|
| Research Support as Topic | 3 | 2017 | 80 | 0.540 |
Why?
|
| Infusions, Intravenous | 24 | 2015 | 429 | 0.520 |
Why?
|
| History, 20th Century | 5 | 2020 | 312 | 0.510 |
Why?
|
| Neutropenia | 14 | 2016 | 215 | 0.510 |
Why?
|
| Choice Behavior | 1 | 2016 | 160 | 0.510 |
Why?
|
| Drug Costs | 1 | 2015 | 62 | 0.510 |
Why?
|
| Health Care Sector | 1 | 2014 | 13 | 0.500 |
Why?
|
| Kidney Neoplasms | 6 | 2012 | 619 | 0.490 |
Why?
|
| Authorship | 1 | 2014 | 24 | 0.490 |
Why?
|
| Antineoplastic Agents, Phytogenic | 7 | 2014 | 276 | 0.490 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 74 | 0.480 |
Why?
|
| Data Mining | 1 | 2014 | 42 | 0.480 |
Why?
|
| Conflict of Interest | 1 | 2014 | 67 | 0.480 |
Why?
|
| Research | 5 | 2009 | 253 | 0.470 |
Why?
|
| Adenocarcinoma | 8 | 2011 | 1169 | 0.470 |
Why?
|
| Neoplasm Metastasis | 11 | 2021 | 1056 | 0.470 |
Why?
|
| Comparative Effectiveness Research | 2 | 2018 | 53 | 0.460 |
Why?
|
| Administration, Oral | 18 | 2007 | 683 | 0.450 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2014 | 69 | 0.450 |
Why?
|
| Physicians | 2 | 2019 | 673 | 0.450 |
Why?
|
| Reimbursement Mechanisms | 3 | 2019 | 41 | 0.450 |
Why?
|
| Predictive Value of Tests | 6 | 2016 | 1672 | 0.440 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2012 | 23 | 0.440 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2022 | 302 | 0.430 |
Why?
|
| Cancer Vaccines | 4 | 2015 | 156 | 0.430 |
Why?
|
| Data Collection | 3 | 2010 | 372 | 0.430 |
Why?
|
| Quality of Health Care | 4 | 2021 | 381 | 0.430 |
Why?
|
| Drug Administration Schedule | 25 | 2015 | 915 | 0.420 |
Why?
|
| Circadian Rhythm | 1 | 2015 | 303 | 0.420 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2008 | 122 | 0.420 |
Why?
|
| Pancreatic Neoplasms | 7 | 2014 | 645 | 0.410 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 2502 | 0.410 |
Why?
|
| Dose-Response Relationship, Drug | 23 | 2014 | 1960 | 0.410 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2014 | 584 | 0.400 |
Why?
|
| History, 21st Century | 3 | 2020 | 175 | 0.400 |
Why?
|
| Hematologic Diseases | 3 | 2011 | 79 | 0.400 |
Why?
|
| Paclitaxel | 9 | 2011 | 460 | 0.400 |
Why?
|
| Pyridines | 4 | 2024 | 310 | 0.390 |
Why?
|
| Polyglutamic Acid | 7 | 1996 | 15 | 0.380 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2010 | 199 | 0.380 |
Why?
|
| Patient Preference | 3 | 2021 | 105 | 0.380 |
Why?
|
| Anticarcinogenic Agents | 1 | 2011 | 70 | 0.380 |
Why?
|
| Prognosis | 11 | 2019 | 3681 | 0.360 |
Why?
|
| Aged, 80 and over | 32 | 2019 | 6511 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2009 | 1197 | 0.350 |
Why?
|
| Costs and Cost Analysis | 2 | 2020 | 153 | 0.350 |
Why?
|
| Clinical Medicine | 1 | 2009 | 34 | 0.350 |
Why?
|
| Privacy | 1 | 2009 | 20 | 0.350 |
Why?
|
| Time Factors | 17 | 2018 | 5215 | 0.340 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 394 | 0.340 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2022 | 645 | 0.340 |
Why?
|
| Etoposide | 7 | 2007 | 196 | 0.330 |
Why?
|
| Hydroxyurea | 9 | 1993 | 239 | 0.330 |
Why?
|
| Placebos | 2 | 2010 | 218 | 0.330 |
Why?
|
| Forecasting | 5 | 2020 | 305 | 0.320 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 589 | 0.320 |
Why?
|
| Diffusion of Innovation | 4 | 2020 | 71 | 0.320 |
Why?
|
| ras Proteins | 1 | 2009 | 128 | 0.310 |
Why?
|
| Disease-Free Survival | 14 | 2017 | 1204 | 0.310 |
Why?
|
| Imides | 7 | 1999 | 26 | 0.310 |
Why?
|
| Human Experimentation | 1 | 2008 | 39 | 0.310 |
Why?
|
| Cyclophosphamide | 9 | 2016 | 299 | 0.310 |
Why?
|
| Risk Assessment | 7 | 2016 | 2261 | 0.310 |
Why?
|
| Isoquinolines | 7 | 1999 | 72 | 0.300 |
Why?
|
| Circulating Tumor DNA | 2 | 2018 | 37 | 0.300 |
Why?
|
| Drug Evaluation | 18 | 2007 | 141 | 0.300 |
Why?
|
| Survival Analysis | 13 | 2018 | 1540 | 0.300 |
Why?
|
| Indoles | 3 | 2022 | 318 | 0.300 |
Why?
|
| Quality Assurance, Health Care | 2 | 2008 | 219 | 0.300 |
Why?
|
| Europe | 4 | 2021 | 309 | 0.300 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 162 | 0.290 |
Why?
|
| Capecitabine | 8 | 2004 | 96 | 0.290 |
Why?
|
| Blood Specimen Collection | 2 | 2018 | 27 | 0.290 |
Why?
|
| Health Policy | 2 | 2020 | 180 | 0.290 |
Why?
|
| Reproducibility of Results | 9 | 2020 | 2704 | 0.280 |
Why?
|
| Biological Products | 1 | 2008 | 143 | 0.280 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 3 | 2002 | 118 | 0.280 |
Why?
|
| Trust | 3 | 2021 | 96 | 0.280 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 6 | 2016 | 165 | 0.280 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2007 | 261 | 0.280 |
Why?
|
| Cytarabine | 7 | 1993 | 218 | 0.270 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 121 | 0.270 |
Why?
|
| Biomarkers | 3 | 2008 | 1722 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2017 | 1313 | 0.260 |
Why?
|
| Cost-Benefit Analysis | 4 | 2016 | 453 | 0.260 |
Why?
|
| Drug Synergism | 10 | 2003 | 303 | 0.260 |
Why?
|
| Prodrugs | 3 | 2004 | 46 | 0.260 |
Why?
|
| Cost of Illness | 2 | 2016 | 150 | 0.260 |
Why?
|
| Quality of Life | 6 | 2021 | 1587 | 0.250 |
Why?
|
| Attitude of Health Personnel | 3 | 2018 | 636 | 0.250 |
Why?
|
| Head and Neck Neoplasms | 14 | 2007 | 1052 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2019 | 508 | 0.250 |
Why?
|
| Patient Safety | 2 | 2017 | 211 | 0.250 |
Why?
|
| Disease Progression | 9 | 2018 | 1534 | 0.250 |
Why?
|
| Adenoma | 2 | 2004 | 237 | 0.240 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2024 | 12 | 0.240 |
Why?
|
| Survival Rate | 12 | 2010 | 1864 | 0.240 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2018 | 154 | 0.240 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2024 | 19 | 0.240 |
Why?
|
| Drugs, Investigational | 3 | 2019 | 37 | 0.240 |
Why?
|
| DNA, Neoplasm | 3 | 2018 | 265 | 0.230 |
Why?
|
| Doxorubicin | 10 | 2016 | 295 | 0.230 |
Why?
|
| Cyclosporine | 3 | 2004 | 236 | 0.230 |
Why?
|
| Ipilimumab | 1 | 2023 | 58 | 0.230 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2023 | 52 | 0.230 |
Why?
|
| Tetrahydrofolates | 4 | 1992 | 13 | 0.220 |
Why?
|
| Positron-Emission Tomography | 3 | 2013 | 329 | 0.220 |
Why?
|
| Phthalazines | 1 | 2023 | 39 | 0.220 |
Why?
|
| Public Health | 1 | 2024 | 129 | 0.220 |
Why?
|
| Tissue Banks | 1 | 2002 | 16 | 0.210 |
Why?
|
| Clinical Trials, Phase II as Topic | 6 | 2015 | 176 | 0.210 |
Why?
|
| Guanine | 2 | 2000 | 208 | 0.210 |
Why?
|
| Biopsy | 3 | 2017 | 1163 | 0.210 |
Why?
|
| Hodgkin Disease | 6 | 1998 | 177 | 0.210 |
Why?
|
| Advisory Committees | 3 | 2021 | 90 | 0.210 |
Why?
|
| Aspirin | 1 | 2003 | 155 | 0.210 |
Why?
|
| Risk Factors | 7 | 2018 | 5416 | 0.200 |
Why?
|
| Drug Labeling | 2 | 2019 | 41 | 0.200 |
Why?
|
| Global Health | 2 | 2020 | 193 | 0.200 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2011 | 78 | 0.200 |
Why?
|
| Financing, Government | 4 | 2016 | 23 | 0.200 |
Why?
|
| Vinblastine | 5 | 1998 | 108 | 0.200 |
Why?
|
| Vaccination | 2 | 2022 | 256 | 0.200 |
Why?
|
| BRCA1 Protein | 1 | 2023 | 200 | 0.200 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2022 | 98 | 0.200 |
Why?
|
| Gene Silencing | 1 | 2002 | 173 | 0.200 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 5 | 2002 | 29 | 0.200 |
Why?
|
| Carcinoma, Small Cell | 3 | 1997 | 134 | 0.200 |
Why?
|
| Cardiovascular Agents | 1 | 2021 | 56 | 0.190 |
Why?
|
| Combined Modality Therapy | 10 | 2019 | 1686 | 0.190 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2000 | 28 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 243 | 0.190 |
Why?
|
| Organoplatinum Compounds | 4 | 2017 | 94 | 0.190 |
Why?
|
| Informed Consent | 3 | 2020 | 266 | 0.190 |
Why?
|
| Karnofsky Performance Status | 3 | 2018 | 40 | 0.190 |
Why?
|
| Sulfonamides | 1 | 2022 | 300 | 0.190 |
Why?
|
| Databases, Factual | 3 | 2019 | 816 | 0.190 |
Why?
|
| Carcinoma | 3 | 2001 | 436 | 0.190 |
Why?
|
| Fertility | 2 | 1992 | 115 | 0.190 |
Why?
|
| Testis | 4 | 1989 | 152 | 0.190 |
Why?
|
| Research Report | 1 | 2020 | 44 | 0.180 |
Why?
|
| Gene Expression Profiling | 5 | 2019 | 1387 | 0.180 |
Why?
|
| Consensus | 5 | 2020 | 336 | 0.180 |
Why?
|
| Betacoronavirus | 2 | 2020 | 257 | 0.180 |
Why?
|
| Natural Language Processing | 1 | 2020 | 37 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2002 | 151 | 0.180 |
Why?
|
| Dissent and Disputes | 1 | 2020 | 28 | 0.180 |
Why?
|
| Checklist | 1 | 2020 | 57 | 0.180 |
Why?
|
| Health Facilities | 1 | 2020 | 36 | 0.180 |
Why?
|
| Carmustine | 3 | 2005 | 70 | 0.180 |
Why?
|
| Communication | 2 | 2021 | 440 | 0.180 |
Why?
|
| Data Anonymization | 1 | 2019 | 1 | 0.180 |
Why?
|
| Tumor Burden | 1 | 2021 | 290 | 0.180 |
Why?
|
| Telemedicine | 2 | 2020 | 168 | 0.180 |
Why?
|
| Guideline Adherence | 2 | 2013 | 224 | 0.180 |
Why?
|
| Thrombocytopenia | 13 | 2004 | 183 | 0.180 |
Why?
|
| Drug Repositioning | 1 | 2019 | 22 | 0.180 |
Why?
|
| Fetus | 1 | 2000 | 226 | 0.180 |
Why?
|
| Ethics, Medical | 3 | 2012 | 306 | 0.180 |
Why?
|
| Public Opinion | 1 | 2019 | 43 | 0.180 |
Why?
|
| Bevacizumab | 3 | 2017 | 281 | 0.170 |
Why?
|
| Remote Consultation | 1 | 2019 | 16 | 0.170 |
Why?
|
| Aminoglycosides | 1 | 1999 | 32 | 0.170 |
Why?
|
| International Cooperation | 2 | 2020 | 127 | 0.170 |
Why?
|
| Patients | 2 | 2019 | 100 | 0.170 |
Why?
|
| Transcriptome | 3 | 2022 | 580 | 0.170 |
Why?
|
| Chromatography, High Pressure Liquid | 7 | 1998 | 316 | 0.170 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 456 | 0.170 |
Why?
|
| Glucuronosyltransferase | 3 | 2014 | 185 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2004 | 424 | 0.170 |
Why?
|
| Health Services Research | 1 | 2019 | 136 | 0.170 |
Why?
|
| Peptides | 4 | 1985 | 639 | 0.170 |
Why?
|
| Publishing | 1 | 2019 | 90 | 0.170 |
Why?
|
| Testicular Neoplasms | 4 | 1992 | 105 | 0.160 |
Why?
|
| Food-Drug Interactions | 2 | 2013 | 18 | 0.160 |
Why?
|
| Program Development | 2 | 2009 | 125 | 0.160 |
Why?
|
| Lymphatic Metastasis | 6 | 2013 | 486 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2019 | 92 | 0.160 |
Why?
|
| Legislation, Drug | 1 | 2018 | 6 | 0.160 |
Why?
|
| Government Regulation | 1 | 2018 | 49 | 0.160 |
Why?
|
| Self Report | 1 | 2019 | 288 | 0.160 |
Why?
|
| Health Information Management | 1 | 2017 | 1 | 0.160 |
Why?
|
| Medical Records | 1 | 2018 | 119 | 0.160 |
Why?
|
| Drug Resistance, Multiple | 1 | 1997 | 20 | 0.160 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 22 | 0.160 |
Why?
|
| Eligibility Determination | 1 | 2017 | 32 | 0.150 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 68 | 0.150 |
Why?
|
| Medicare | 5 | 2014 | 408 | 0.150 |
Why?
|
| DNA Mismatch Repair | 2 | 2018 | 52 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2002 | 630 | 0.150 |
Why?
|
| Retrospective Studies | 12 | 2022 | 8476 | 0.150 |
Why?
|
| Cardiovascular Diseases | 3 | 2021 | 827 | 0.150 |
Why?
|
| Proportional Hazards Models | 6 | 2021 | 860 | 0.150 |
Why?
|
| Prospective Studies | 13 | 2022 | 4212 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2019 | 861 | 0.150 |
Why?
|
| Tamoxifen | 1 | 1997 | 168 | 0.140 |
Why?
|
| Drug Interactions | 7 | 2007 | 248 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2018 | 170 | 0.140 |
Why?
|
| Stakeholder Participation | 1 | 2016 | 19 | 0.140 |
Why?
|
| Oncology Nursing | 1 | 2016 | 8 | 0.140 |
Why?
|
| Insurance Claim Review | 3 | 2008 | 41 | 0.140 |
Why?
|
| Ovary | 3 | 1989 | 258 | 0.140 |
Why?
|
| Area Under Curve | 8 | 2007 | 334 | 0.130 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 87 | 0.130 |
Why?
|
| Interferon-alpha | 5 | 2004 | 234 | 0.130 |
Why?
|
| Radiation Oncology | 1 | 2017 | 119 | 0.130 |
Why?
|
| Salvage Therapy | 2 | 2010 | 233 | 0.130 |
Why?
|
| Quinazolines | 4 | 2003 | 220 | 0.130 |
Why?
|
| Age Factors | 5 | 2016 | 1849 | 0.130 |
Why?
|
| Bone Marrow Diseases | 2 | 1993 | 40 | 0.130 |
Why?
|
| Aging | 2 | 2012 | 693 | 0.130 |
Why?
|
| Frail Elderly | 2 | 2014 | 71 | 0.130 |
Why?
|
| Depsipeptides | 1 | 2015 | 29 | 0.130 |
Why?
|
| GTP Phosphohydrolases | 1 | 2015 | 71 | 0.130 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 1992 | 95 | 0.130 |
Why?
|
| Asia | 1 | 2015 | 95 | 0.130 |
Why?
|
| Liver | 3 | 2004 | 1229 | 0.130 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2007 | 138 | 0.130 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 59 | 0.130 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2004 | 112 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 468 | 0.130 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 48 | 0.130 |
Why?
|
| Phenotype | 6 | 2014 | 2389 | 0.130 |
Why?
|
| Floxuridine | 2 | 1993 | 11 | 0.130 |
Why?
|
| Health Care Reform | 1 | 2016 | 90 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 311 | 0.130 |
Why?
|
| Trimetrexate | 3 | 2002 | 4 | 0.120 |
Why?
|
| Folic Acid Antagonists | 2 | 1992 | 19 | 0.120 |
Why?
|
| Dacarbazine | 2 | 1998 | 102 | 0.120 |
Why?
|
| Leukopenia | 9 | 1997 | 65 | 0.120 |
Why?
|
| Lymphoma | 5 | 2004 | 262 | 0.120 |
Why?
|
| Cohort Studies | 8 | 2019 | 2765 | 0.120 |
Why?
|
| Adolescent | 10 | 2018 | 8988 | 0.120 |
Why?
|
| Animals | 18 | 2013 | 26706 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2016 | 592 | 0.120 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 526 | 0.120 |
Why?
|
| Bone Marrow | 9 | 2001 | 435 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2015 | 136 | 0.120 |
Why?
|
| Disease Management | 3 | 2021 | 328 | 0.120 |
Why?
|
| Exons | 1 | 2015 | 452 | 0.120 |
Why?
|
| Geriatrics | 1 | 2014 | 61 | 0.120 |
Why?
|
| Tegafur | 4 | 2001 | 17 | 0.120 |
Why?
|
| Kallikreins | 1 | 2013 | 47 | 0.120 |
Why?
|
| Pediatrics | 1 | 2018 | 344 | 0.120 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2016 | 155 | 0.120 |
Why?
|
| Unnecessary Procedures | 1 | 2013 | 51 | 0.110 |
Why?
|
| Multivariate Analysis | 5 | 2013 | 999 | 0.110 |
Why?
|
| Anthracenes | 1 | 1993 | 16 | 0.110 |
Why?
|
| Heart Failure | 2 | 2021 | 1207 | 0.110 |
Why?
|
| Naphthalimides | 7 | 1999 | 17 | 0.110 |
Why?
|
| Device Approval | 1 | 2013 | 13 | 0.110 |
Why?
|
| Anilides | 1 | 2013 | 47 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 110 | 0.110 |
Why?
|
| Topotecan | 4 | 1998 | 45 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2014 | 129 | 0.110 |
Why?
|
| Gonads | 1 | 1992 | 19 | 0.110 |
Why?
|
| Organophosphonates | 7 | 1999 | 50 | 0.110 |
Why?
|
| Obesity | 2 | 2015 | 964 | 0.110 |
Why?
|
| Recombinant Proteins | 8 | 2003 | 1018 | 0.110 |
Why?
|
| Sepsis | 1 | 1996 | 307 | 0.110 |
Why?
|
| Kidney Diseases | 4 | 2003 | 416 | 0.110 |
Why?
|
| Adenine | 7 | 1999 | 85 | 0.110 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 16 | 0.110 |
Why?
|
| Antiemetics | 1 | 2013 | 98 | 0.110 |
Why?
|
| Young Adult | 4 | 2019 | 5977 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2016 | 78 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2013 | 297 | 0.100 |
Why?
|
| Neuroendocrine Tumors | 1 | 2014 | 105 | 0.100 |
Why?
|
| Thymidylate Synthase | 2 | 2001 | 13 | 0.100 |
Why?
|
| Research Subjects | 2 | 2011 | 73 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 372 | 0.100 |
Why?
|
| Patient Advocacy | 1 | 2012 | 49 | 0.100 |
Why?
|
| Injections, Intravenous | 4 | 2004 | 242 | 0.100 |
Why?
|
| Echinomycin | 1 | 1991 | 2 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 853 | 0.100 |
Why?
|
| Magnesium Deficiency | 2 | 1982 | 5 | 0.100 |
Why?
|
| Prostate-Specific Antigen | 1 | 2013 | 353 | 0.100 |
Why?
|
| Hepatectomy | 2 | 2014 | 166 | 0.100 |
Why?
|
| Premenopause | 1 | 2011 | 54 | 0.100 |
Why?
|
| Interleukin-17 | 1 | 2011 | 101 | 0.100 |
Why?
|
| Cancer Care Facilities | 1 | 2011 | 28 | 0.100 |
Why?
|
| Pharmacoepidemiology | 1 | 2010 | 6 | 0.100 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 124 | 0.100 |
Why?
|
| Carbazoles | 1 | 2011 | 51 | 0.100 |
Why?
|
| Diphosphonates | 1 | 2011 | 36 | 0.100 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2011 | 20 | 0.100 |
Why?
|
| Geriatric Assessment | 1 | 2012 | 166 | 0.090 |
Why?
|
| Chemoprevention | 1 | 2011 | 92 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2011 | 45 | 0.090 |
Why?
|
| Molecular Biology | 1 | 2011 | 89 | 0.090 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 4 | 1985 | 32 | 0.090 |
Why?
|
| Mandatory Testing | 1 | 2010 | 3 | 0.090 |
Why?
|
| Remission Induction | 9 | 1997 | 722 | 0.090 |
Why?
|
| Stereoisomerism | 5 | 1990 | 102 | 0.090 |
Why?
|
| Standard of Care | 1 | 2011 | 79 | 0.090 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 250 | 0.090 |
Why?
|
| Formyltetrahydrofolates | 1 | 1990 | 1 | 0.090 |
Why?
|
| Imidazoles | 1 | 2011 | 162 | 0.090 |
Why?
|
| Algorithms | 4 | 2015 | 1830 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 1 | 2010 | 100 | 0.090 |
Why?
|
| Bone Density | 1 | 2011 | 209 | 0.090 |
Why?
|
| Thymidine | 2 | 1986 | 59 | 0.090 |
Why?
|
| Infertility, Male | 1 | 1989 | 24 | 0.090 |
Why?
|
| Pyrroles | 1 | 2010 | 184 | 0.090 |
Why?
|
| Stomatitis | 5 | 2004 | 30 | 0.090 |
Why?
|
| Splenectomy | 1 | 1989 | 82 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 1 | 1990 | 177 | 0.090 |
Why?
|
| Adjuvants, Immunologic | 1 | 2010 | 167 | 0.080 |
Why?
|
| Software Design | 1 | 2008 | 17 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1201 | 0.080 |
Why?
|
| Attitude | 1 | 2009 | 127 | 0.080 |
Why?
|
| Radiation Injuries | 1 | 1989 | 156 | 0.080 |
Why?
|
| France | 2 | 2020 | 47 | 0.080 |
Why?
|
| Mortality | 1 | 2009 | 150 | 0.080 |
Why?
|
| Qualitative Research | 1 | 2009 | 256 | 0.080 |
Why?
|
| Filgrastim | 3 | 2003 | 56 | 0.080 |
Why?
|
| Databases, Genetic | 1 | 2009 | 260 | 0.080 |
Why?
|
| Genitalia, Male | 1 | 1988 | 24 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 1992 | 1077 | 0.080 |
Why?
|
| Genitalia, Female | 1 | 1988 | 25 | 0.080 |
Why?
|
| Kinetics | 6 | 1990 | 1513 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 2011 | 1824 | 0.080 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2007 | 41 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 2585 | 0.080 |
Why?
|
| Glycolipids | 1 | 2007 | 29 | 0.080 |
Why?
|
| Half-Life | 4 | 2004 | 96 | 0.080 |
Why?
|
| Leadership | 1 | 2009 | 133 | 0.080 |
Why?
|
| Physician-Patient Relations | 2 | 2011 | 610 | 0.080 |
Why?
|
| SEER Program | 3 | 2016 | 190 | 0.080 |
Why?
|
| Genotype | 4 | 2014 | 1853 | 0.080 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2007 | 37 | 0.070 |
Why?
|
| Sex | 1 | 1987 | 6 | 0.070 |
Why?
|
| Palliative Care | 1 | 2009 | 257 | 0.070 |
Why?
|
| Ketoconazole | 1 | 2007 | 25 | 0.070 |
Why?
|
| Carboplatin | 3 | 2008 | 286 | 0.070 |
Why?
|
| Radiotherapy | 1 | 1989 | 328 | 0.070 |
Why?
|
| Stomach Neoplasms | 3 | 1994 | 266 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 378 | 0.070 |
Why?
|
| Nogalamycin | 1 | 1986 | 2 | 0.070 |
Why?
|
| Bilirubin | 3 | 2007 | 125 | 0.070 |
Why?
|
| Recreation | 1 | 2006 | 7 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2003 | 114 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2015 | 3267 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2001 | 224 | 0.070 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1987 | 186 | 0.070 |
Why?
|
| Physical Exertion | 1 | 2006 | 39 | 0.070 |
Why?
|
| Daunorubicin | 1 | 1986 | 78 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 4 | 2004 | 121 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2007 | 234 | 0.070 |
Why?
|
| Antifungal Agents | 1 | 2007 | 117 | 0.070 |
Why?
|
| Risk | 2 | 2010 | 674 | 0.070 |
Why?
|
| Interferon Type I | 1 | 1987 | 175 | 0.070 |
Why?
|
| Canada | 2 | 2017 | 202 | 0.070 |
Why?
|
| Infertility | 2 | 1989 | 37 | 0.070 |
Why?
|
| Pyrazines | 2 | 1998 | 92 | 0.070 |
Why?
|
| Bleomycin | 5 | 1998 | 98 | 0.070 |
Why?
|
| Fatigue | 4 | 2011 | 175 | 0.060 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 69 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2006 | 85 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2004 | 552 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 2272 | 0.060 |
Why?
|
| Phenobarbital | 1 | 2004 | 33 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 840 | 0.060 |
Why?
|
| Incidence | 1 | 2009 | 1578 | 0.060 |
Why?
|
| Maytansine | 1 | 2004 | 9 | 0.060 |
Why?
|
| Regression Analysis | 2 | 1997 | 596 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2021 | 751 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2006 | 236 | 0.060 |
Why?
|
| Urogenital Neoplasms | 3 | 2008 | 23 | 0.060 |
Why?
|
| Nurses | 1 | 2004 | 40 | 0.060 |
Why?
|
| Motor Activity | 1 | 2006 | 327 | 0.060 |
Why?
|
| Antibody Specificity | 1 | 2003 | 129 | 0.060 |
Why?
|
| Idoxuridine | 2 | 1993 | 16 | 0.060 |
Why?
|
| Hypnotics and Sedatives | 1 | 2004 | 127 | 0.060 |
Why?
|
| Magnesium | 3 | 1982 | 177 | 0.060 |
Why?
|
| Exercise | 1 | 2006 | 315 | 0.060 |
Why?
|
| Follow-Up Studies | 5 | 2004 | 3639 | 0.050 |
Why?
|
| Child | 6 | 2018 | 6933 | 0.050 |
Why?
|
| Patient Compliance | 3 | 2001 | 228 | 0.050 |
Why?
|
| Azirines | 1 | 1982 | 3 | 0.050 |
Why?
|
| Aziridines | 1 | 1982 | 9 | 0.050 |
Why?
|
| Acetylation | 4 | 1996 | 121 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2003 | 162 | 0.050 |
Why?
|
| Benzoquinones | 1 | 1982 | 27 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2022 | 135 | 0.050 |
Why?
|
| DNA Adducts | 1 | 2002 | 21 | 0.050 |
Why?
|
| Insulin | 2 | 1985 | 1160 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 137 | 0.050 |
Why?
|
| Colonic Polyps | 1 | 2003 | 127 | 0.050 |
Why?
|
| Oxonic Acid | 1 | 2001 | 8 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 325 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2004 | 1759 | 0.050 |
Why?
|
| Aminoquinolines | 1 | 2001 | 17 | 0.050 |
Why?
|
| Indenes | 1 | 2001 | 9 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2003 | 239 | 0.050 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2001 | 9 | 0.050 |
Why?
|
| Intercalating Agents | 2 | 1993 | 12 | 0.050 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2001 | 27 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 84 | 0.050 |
Why?
|
| Lymphoma, Follicular | 1 | 2001 | 70 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2002 | 153 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2003 | 267 | 0.050 |
Why?
|
| Leukemia, Myeloid | 1 | 2002 | 249 | 0.050 |
Why?
|
| World Health Organization | 1 | 2020 | 103 | 0.050 |
Why?
|
| Piperazines | 1 | 2022 | 272 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 532 | 0.050 |
Why?
|
| Cause of Death | 1 | 2001 | 277 | 0.050 |
Why?
|
| Acute Disease | 1 | 2002 | 827 | 0.050 |
Why?
|
| Specimen Handling | 2 | 2011 | 98 | 0.050 |
Why?
|
| Drug Therapy, Combination | 4 | 2004 | 895 | 0.050 |
Why?
|
| Cell Line | 6 | 1988 | 2476 | 0.040 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2019 | 6 | 0.040 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1979 | 10 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 1999 | 911 | 0.040 |
Why?
|
| DNA Repair | 1 | 2002 | 356 | 0.040 |
Why?
|
| Morals | 1 | 2020 | 92 | 0.040 |
Why?
|
| Policy Making | 1 | 2019 | 62 | 0.040 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2000 | 153 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 977 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 115 | 0.040 |
Why?
|
| Gallbladder Neoplasms | 1 | 1999 | 22 | 0.040 |
Why?
|
| Melphalan | 1 | 1999 | 98 | 0.040 |
Why?
|
| Kidney Tubules | 1 | 1979 | 95 | 0.040 |
Why?
|
| Biological Availability | 1 | 1998 | 92 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 141 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 1998 | 40 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2018 | 80 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2018 | 43 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 1997 | 292 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2019 | 117 | 0.040 |
Why?
|
| Common Data Elements | 1 | 2017 | 1 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 3 | 2004 | 270 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 158 | 0.040 |
Why?
|
| Pathology, Clinical | 1 | 2018 | 33 | 0.040 |
Why?
|
| Bile Duct Neoplasms | 1 | 1999 | 79 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 819 | 0.040 |
Why?
|
| Observation | 2 | 2008 | 37 | 0.040 |
Why?
|
| Developed Countries | 1 | 2017 | 24 | 0.040 |
Why?
|
| Databases, Nucleic Acid | 1 | 2017 | 41 | 0.040 |
Why?
|
| Endpoint Determination | 2 | 2010 | 60 | 0.040 |
Why?
|
| Body Weight | 2 | 1996 | 458 | 0.040 |
Why?
|
| Hospitalization | 2 | 2016 | 851 | 0.040 |
Why?
|
| Annual Reports as Topic | 1 | 2017 | 5 | 0.040 |
Why?
|
| Nausea | 3 | 2004 | 175 | 0.040 |
Why?
|
| Professional Competence | 1 | 2017 | 68 | 0.040 |
Why?
|
| Developing Countries | 1 | 2017 | 71 | 0.040 |
Why?
|
| Serum Albumin | 2 | 1995 | 130 | 0.040 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2008 | 81 | 0.040 |
Why?
|
| Pregnancy | 2 | 2000 | 2901 | 0.040 |
Why?
|
| Genital Neoplasms, Female | 2 | 2008 | 107 | 0.040 |
Why?
|
| Leukocyte Count | 4 | 1996 | 220 | 0.030 |
Why?
|
| Sex Factors | 2 | 2016 | 1053 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 1170 | 0.030 |
Why?
|
| Taxoids | 1 | 2016 | 129 | 0.030 |
Why?
|
| Spermatogenesis | 2 | 1989 | 37 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2016 | 160 | 0.030 |
Why?
|
| Israel | 1 | 2015 | 55 | 0.030 |
Why?
|
| Spain | 1 | 2015 | 33 | 0.030 |
Why?
|
| Asthenia | 2 | 1985 | 4 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 1979 | 296 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1618 | 0.030 |
Why?
|
| Federal Government | 1 | 2015 | 29 | 0.030 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1994 | 15 | 0.030 |
Why?
|
| Digestive System | 3 | 1986 | 42 | 0.030 |
Why?
|
| ROC Curve | 2 | 2008 | 752 | 0.030 |
Why?
|
| Outpatients | 2 | 2000 | 94 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2015 | 59 | 0.030 |
Why?
|
| Protein Binding | 3 | 1985 | 1462 | 0.030 |
Why?
|
| Cladribine | 1 | 1994 | 35 | 0.030 |
Why?
|
| Research Personnel | 1 | 2015 | 67 | 0.030 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 1994 | 17 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2015 | 116 | 0.030 |
Why?
|
| Vidarabine Phosphate | 1 | 1994 | 5 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 567 | 0.030 |
Why?
|
| Educational Status | 1 | 2014 | 190 | 0.030 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1994 | 66 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 150 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 691 | 0.030 |
Why?
|
| Therapeutic Human Experimentation | 1 | 1993 | 20 | 0.030 |
Why?
|
| Nontherapeutic Human Experimentation | 1 | 1993 | 20 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 1999 | 747 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 1993 | 79 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2014 | 70 | 0.030 |
Why?
|
| Genome-Wide Association Study | 2 | 2011 | 1621 | 0.030 |
Why?
|
| Peer Review, Research | 1 | 2013 | 36 | 0.030 |
Why?
|
| Electrocardiography | 2 | 1993 | 478 | 0.030 |
Why?
|
| Pharmacy | 1 | 2013 | 7 | 0.030 |
Why?
|
| Aminopterin | 1 | 1992 | 5 | 0.030 |
Why?
|
| Astrocytoma | 1 | 1993 | 82 | 0.030 |
Why?
|
| Peptide Biosynthesis | 2 | 1982 | 17 | 0.030 |
Why?
|
| Thiophenes | 1 | 1992 | 48 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 1993 | 238 | 0.030 |
Why?
|
| Methyltransferases | 1 | 1994 | 183 | 0.030 |
Why?
|
| Monocytes | 1 | 1994 | 216 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1992 | 59 | 0.030 |
Why?
|
| Health Services for the Aged | 1 | 2012 | 27 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 357 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 318 | 0.020 |
Why?
|
| Models, Biological | 5 | 2002 | 1752 | 0.020 |
Why?
|
| Glioblastoma | 1 | 1993 | 255 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 1991 | 0.020 |
Why?
|
| Intestinal Absorption | 2 | 2002 | 124 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 1993 | 150 | 0.020 |
Why?
|
| Creatinine | 2 | 2003 | 339 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 881 | 0.020 |
Why?
|
| Public Sector | 1 | 2010 | 12 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 1990 | 102 | 0.020 |
Why?
|
| Drug Resistance | 2 | 1993 | 256 | 0.020 |
Why?
|
| Private Sector | 1 | 2010 | 19 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 339 | 0.020 |
Why?
|
| Cells, Cultured | 4 | 1985 | 2839 | 0.020 |
Why?
|
| Anorexia | 2 | 2001 | 30 | 0.020 |
Why?
|
| Deoxyuracil Nucleotides | 1 | 1990 | 5 | 0.020 |
Why?
|
| Mechlorethamine | 2 | 1998 | 11 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 473 | 0.020 |
Why?
|
| Prostaglandins | 1 | 2010 | 43 | 0.020 |
Why?
|
| Buffers | 1 | 1990 | 26 | 0.020 |
Why?
|
| Procarbazine | 2 | 1998 | 40 | 0.020 |
Why?
|
| Fever | 1 | 2011 | 125 | 0.020 |
Why?
|
| Cell-Free System | 1 | 1990 | 51 | 0.020 |
Why?
|
| Pyrimidines | 1 | 1992 | 370 | 0.020 |
Why?
|
| Vincristine | 2 | 1998 | 111 | 0.020 |
Why?
|
| Alleles | 2 | 2004 | 1129 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1989 | 47 | 0.020 |
Why?
|
| Prednisone | 2 | 1998 | 258 | 0.020 |
Why?
|
| Spermatozoa | 1 | 1989 | 62 | 0.020 |
Why?
|
| Cell Membrane | 2 | 1983 | 666 | 0.020 |
Why?
|
| Survivors | 1 | 2010 | 227 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1990 | 187 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 1988 | 57 | 0.020 |
Why?
|
| Drug Therapy | 1 | 1989 | 70 | 0.020 |
Why?
|
| Thoracic Neoplasms | 1 | 2008 | 64 | 0.020 |
Why?
|
| Pain | 1 | 2011 | 390 | 0.020 |
Why?
|
| Serum Albumin, Bovine | 1 | 1988 | 45 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2010 | 321 | 0.020 |
Why?
|
| Lipid Droplets | 1 | 2007 | 16 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 44 | 0.020 |
Why?
|
| Laryngeal Neoplasms | 1 | 1988 | 89 | 0.020 |
Why?
|
| Silicon Dioxide | 1 | 1988 | 39 | 0.020 |
Why?
|
| Kidney | 2 | 1986 | 1245 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1989 | 180 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 1989 | 232 | 0.020 |
Why?
|
| DNA, Recombinant | 1 | 1987 | 67 | 0.020 |
Why?
|
| Biotransformation | 2 | 1990 | 50 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2007 | 77 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 179 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1989 | 263 | 0.020 |
Why?
|
| Menogaril | 1 | 1986 | 3 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1987 | 147 | 0.020 |
Why?
|
| Sarcoma | 1 | 2008 | 215 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1988 | 286 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 1987 | 167 | 0.020 |
Why?
|
| Thymine | 1 | 1986 | 17 | 0.020 |
Why?
|
| Ethics Committees, Research | 1 | 2006 | 33 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 2008 | 196 | 0.020 |
Why?
|
| Inpatients | 1 | 1989 | 298 | 0.020 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1985 | 30 | 0.020 |
Why?
|
| Testosterone | 1 | 1987 | 271 | 0.020 |
Why?
|
| Clone Cells | 1 | 1985 | 213 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2005 | 126 | 0.020 |
Why?
|
| Phenylenediamines | 1 | 2004 | 5 | 0.020 |
Why?
|
| Calcium | 1 | 1990 | 1156 | 0.020 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2005 | 67 | 0.020 |
Why?
|
| Anemia | 2 | 2003 | 128 | 0.020 |
Why?
|
| Transaminases | 1 | 2004 | 34 | 0.020 |
Why?
|
| Nucleotides | 1 | 1985 | 95 | 0.020 |
Why?
|
| Platelet Count | 1 | 1984 | 92 | 0.020 |
Why?
|
| Nurse-Patient Relations | 1 | 2004 | 13 | 0.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2004 | 15 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2004 | 85 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 1982 | 292 | 0.010 |
Why?
|
| Dogs | 1 | 1985 | 686 | 0.010 |
Why?
|
| Mice | 2 | 1996 | 11439 | 0.010 |
Why?
|
| Microtubules | 1 | 2004 | 121 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 1985 | 146 | 0.010 |
Why?
|
| Medicaid | 1 | 2006 | 217 | 0.010 |
Why?
|
| Benzamides | 1 | 2004 | 229 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 1986 | 482 | 0.010 |
Why?
|
| Diarrhea | 1 | 2004 | 182 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1721 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 2357 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2006 | 329 | 0.010 |
Why?
|
| CD56 Antigen | 1 | 2002 | 18 | 0.010 |
Why?
|
| Chromium | 1 | 2002 | 17 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2004 | 165 | 0.010 |
Why?
|
| Dysgerminoma | 1 | 1982 | 7 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 303 | 0.010 |
Why?
|
| Nitrosourea Compounds | 1 | 1982 | 9 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 2002 | 12 | 0.010 |
Why?
|
| Electrolytes | 1 | 1982 | 52 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 279 | 0.010 |
Why?
|
| Glucuronides | 1 | 2002 | 34 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 411 | 0.010 |
Why?
|
| Population | 1 | 2002 | 35 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2002 | 250 | 0.010 |
Why?
|
| Muscles | 1 | 1982 | 194 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 2001 | 16 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2002 | 349 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 546 | 0.010 |
Why?
|
| Amenorrhea | 1 | 1981 | 27 | 0.010 |
Why?
|
| Nucleic Acids | 1 | 1982 | 31 | 0.010 |
Why?
|
| Sodium Azide | 1 | 1981 | 5 | 0.010 |
Why?
|
| Azides | 1 | 1981 | 11 | 0.010 |
Why?
|
| Uric Acid | 1 | 1982 | 139 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 1564 | 0.010 |
Why?
|
| Dihydrouracil Dehydrogenase (NAD+) | 1 | 2001 | 1 | 0.010 |
Why?
|
| Demography | 1 | 2002 | 177 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 1981 | 102 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 364 | 0.010 |
Why?
|
| Cell Division | 1 | 1982 | 696 | 0.010 |
Why?
|
| Hormones | 1 | 1981 | 141 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 267 | 0.010 |
Why?
|
| Haplorhini | 1 | 1981 | 82 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2002 | 399 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2001 | 170 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2002 | 680 | 0.010 |
Why?
|
| Ovulation | 1 | 1980 | 68 | 0.010 |
Why?
|
| Alkylating Agents | 1 | 1980 | 32 | 0.010 |
Why?
|
| Gallium Radioisotopes | 1 | 1980 | 32 | 0.010 |
Why?
|
| Estradiol | 1 | 1981 | 252 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 1982 | 385 | 0.010 |
Why?
|
| Binding Sites | 1 | 1983 | 1104 | 0.010 |
Why?
|
| Temperature | 1 | 1981 | 396 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1981 | 269 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 1979 | 37 | 0.010 |
Why?
|
| Infusion Pumps | 2 | 1989 | 25 | 0.010 |
Why?
|
| Radiotherapy Dosage | 2 | 1992 | 468 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1985 | 1471 | 0.010 |
Why?
|
| Hearing | 1 | 1979 | 59 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1979 | 124 | 0.010 |
Why?
|
| Hypoxia | 1 | 2004 | 642 | 0.010 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 1998 | 15 | 0.010 |
Why?
|
| Random Allocation | 2 | 1989 | 332 | 0.010 |
Why?
|
| Cell Count | 1 | 1998 | 197 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1998 | 196 | 0.010 |
Why?
|
| Isotretinoin | 1 | 1997 | 23 | 0.010 |
Why?
|
| Antidotes | 1 | 1997 | 23 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1997 | 117 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 1988 | 1041 | 0.010 |
Why?
|
| Brain | 1 | 1986 | 2220 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 3366 | 0.010 |
Why?
|
| Linear Models | 1 | 1996 | 421 | 0.010 |
Why?
|
| Cyclohexenes | 1 | 1994 | 5 | 0.010 |
Why?
|
| Benzofurans | 1 | 1994 | 8 | 0.010 |
Why?
|
| Blindness | 1 | 1994 | 41 | 0.010 |
Why?
|
| Rats | 1 | 1981 | 4004 | 0.010 |
Why?
|
| Consent Forms | 1 | 1993 | 11 | 0.010 |
Why?
|
| Personal Autonomy | 1 | 1993 | 112 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1993 | 67 | 0.010 |
Why?
|
| Pancoast Syndrome | 1 | 1990 | 2 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1991 | 157 | 0.010 |
Why?
|
| Trifluoperazine | 1 | 1990 | 10 | 0.010 |
Why?
|
| Diltiazem | 1 | 1990 | 17 | 0.010 |
Why?
|
| Nifedipine | 1 | 1990 | 28 | 0.010 |
Why?
|
| Verapamil | 1 | 1990 | 48 | 0.010 |
Why?
|
| Biological Transport | 1 | 1990 | 396 | 0.010 |
Why?
|
| Leukemia L1210 | 1 | 1988 | 12 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1988 | 49 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 1988 | 63 | 0.000 |
Why?
|
| Attitude to Health | 1 | 1989 | 220 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1988 | 493 | 0.000 |
Why?
|
| Transplantation, Autologous | 1 | 1988 | 331 | 0.000 |
Why?
|
| DNA Damage | 1 | 1988 | 366 | 0.000 |
Why?
|
| Models, Statistical | 1 | 1989 | 575 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1982 | 103 | 0.000 |
Why?
|
| False Negative Reactions | 1 | 1980 | 63 | 0.000 |
Why?
|
| Lymphography | 1 | 1980 | 27 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1980 | 274 | 0.000 |
Why?
|
| False Positive Reactions | 1 | 1980 | 216 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1979 | 36 | 0.000 |
Why?
|
| Radionuclide Imaging | 1 | 1980 | 220 | 0.000 |
Why?
|
| Nervous System | 1 | 1979 | 87 | 0.000 |
Why?
|
| Heart | 1 | 1979 | 557 | 0.000 |
Why?
|